D.Western Therapeutics to Collaborate on Next-Generation Eye Disease Treatments

MT Newswires Live

Apr 29, 2025

D. Western Therapeutics Institute (TYO:4576) has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.

The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.

The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.

The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.

Price (JPY): $108.00, Change: $+2.0, Percent Change: +1.89%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531574299"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531574299\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531574299?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 07:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531574299","market":"nz","top_or_hot":-1,"title":"D.Western Therapeutics to Collaborate on Next-Generation Eye Disease Treatments","media":"MT Newswires Live","content":"<html><body><p> D. Western <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Institute (TYO:4576) has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.</p><p>The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.</p><p>The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.</p><p>The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.</p><p>Price (JPY): $108.00, Change: $+2.0, Percent Change: +1.89%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>D.Western Therapeutics to Collaborate on Next-Generation Eye Disease Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nD.Western Therapeutics to Collaborate on Next-Generation Eye Disease Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-29 07:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> D. Western <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Institute (TYO:4576) has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.</p><p>The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.</p><p>The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.</p><p>The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.</p><p>Price (JPY): $108.00, Change: $+2.0, Percent Change: +1.89%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JPY","symbol_name":"Lazard Japanese Equity ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2531574299","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531574299","pubTimestamp":1745883668,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"D. Western Therapeutics Institute  has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.Price : $108.00, Change: $+2.0, Percent Change: +1.89%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JPY":"Lazard Japanese Equity ETF","BK4007":"制药","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"D.Western Therapeutics将合作开发下一代眼病治疗方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JPY":1,"LENZ":1},"content_text":"D. Western Therapeutics Institute (TYO:4576) has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.Price (JPY): $108.00, Change: $+2.0, Percent Change: +1.89%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}